Fineline Cube

Follow:
14422 Articles
Fosun Kairos Secures NMPA Approval for Second CAR‑T Product, FKC889, Targeting Relapsed/Refractory B‑Cell ALL
CompanyDrug

Fosun Kairos Secures NMPA Approval for Second CAR‑T Product, FKC889, Targeting Relapsed/Refractory B‑Cell ALL

Mabwell Bioscience Hits Phase II Milestone with First‑Patient Dose of 9MW3011, the Only Anti‑TMPRSS6 Monoclonal Antibody for Polycythemia Vera
Drug

Mabwell Bioscience Hits Phase II Milestone with First‑Patient Dose of 9MW3011, the Only Anti‑TMPRSS6 Monoclonal Antibody for Polycythemia Vera

Burning Rock Secures Japanese Approval for OncoGuide OncoScreen Plus CDx, Enabling Capivasertib Therapy
Medical Device

Burning Rock Secures Japanese Approval for OncoGuide OncoScreen Plus CDx, Enabling Capivasertib Therapy

FibroGen Launches Phase 2 Dose‑Optimization Trial for CD46‑Targeted ADC FG‑3246 in Metastatic Castration‑Resistant Prostate Cancer
CompanyDrug

FibroGen Launches Phase 2 Dose‑Optimization Trial for CD46‑Targeted ADC FG‑3246 in Metastatic Castration‑Resistant Prostate Cancer

DualityBio Initiates Global Phase Ia/Ib Study of ADAM9‑Targeting ADC DB‑1317
Drug

DualityBio Initiates Global Phase Ia/Ib Study of ADAM9‑Targeting ADC DB‑1317

Trump Administration Expands Section 232 Tariffs on Robotics, Industrial Machinery and Medical Devices
CompanyMedical Device

Trump Administration Expands Section 232 Tariffs on Robotics, Industrial Machinery and Medical Devices

Hengrui Pharma & Glenmark Partner on Trastuzumab Rezecan ADC for HER2‑Positive Lung Cancer
CompanyDeals

Hengrui Pharma & Glenmark Partner on Trastuzumab Rezecan ADC for HER2‑Positive Lung Cancer

Jiangsu Hengrui Receives NMPA Acceptance for SHR7280 Oral GnRH Antagonist
CompanyDrug

Jiangsu Hengrui Receives NMPA Acceptance for SHR7280 Oral GnRH Antagonist

Johnson & Johnson Announces International Withdrawal of Linx Reflux System
CompanyMedical Device

Johnson & Johnson Announces International Withdrawal of Linx Reflux System

RM Bio‑Tech Secures CDE Approval for HF001 Stem‑Cell Therapy in Type 2 Diabetes
CompanyDrug

RM Bio‑Tech Secures CDE Approval for HF001 Stem‑Cell Therapy in Type 2 Diabetes

Jiangsu Hengrui’s Adebrelimab New Indication Accepted by NMPA for Stage II‑IIIB NSCLC
CompanyDrug

Jiangsu Hengrui’s Adebrelimab New Indication Accepted by NMPA for Stage II‑IIIB NSCLC

Yantai Dongcheng Secures NMPA Approval for 225Ac‑LNC1011 Alpha‑Particle Radiopharmaceutical to Target Prostate Cancer
CompanyDrug

Yantai Dongcheng Secures NMPA Approval for 225Ac‑LNC1011 Alpha‑Particle Radiopharmaceutical to Target Prostate Cancer